What is InMed’s mission? In this interview with Shadd Dales of The Dales Report, InMed CEO, Eric A. Adams, talks about InMed’s pharmaceutical programs and expansion into the health and wellness sector with the recent acquisition of rare cannabinoid manufacturer, BayMedica.
Read the article and watch the full video at The Dales Report.
Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,
A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8
© Copyright 2025 InMed Pharmaceuticals Inc.
"*" indicates required fields